Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) issued its earnings results on Tuesday. Kalaris Therapeutics Stock PerformanceShares of Kalaris Therapeutics stock opened at $3.94 on Tuesday. Kalaris Therapeutics has a one year low of $2.14 and a one year high of $11.88. RTW Investments LP bought a new position in Kalaris Therapeutics during the 4th quarter valued at about $10,972,000. Further ReadingReceive News & Ratings for Kalaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.